What impact could Medicaid policy changes have on cell therapy reimbursement?
Proposed Medicaid policy changes, including outcome-based and annuity payment models, aim to enhance access to costly cell and gene therapies (CGTs) while addressing state budget constraints[6]. These changes could alleviate immediate financial burdens by spreading costs over time and tying payments to patient outcomes[6].
Current reimbursement models often leave states with stringent utilization controls, limiting access to innovative treatments, particularly for high-cost therapies[5]. If successfully implemented, these policy adjustments could not only reduce hospital budget impacts but also enhance patient access to essential therapies that address severe health conditions[3].
Créez votre compte pour conserver cette réponse et la reprendre plus tard.
Examinons les alternatives :
- Modifier la requête.
- Démarrer une nouvelle conversation.
- Supprimer des sources (si elles ont été ajoutées manuellement).
